StockMacro
Menu

ImmunityBio

$6.02 -24% in 6 monthsMarket cap $6.4B

IBRX on XNAS, Health Care, ImmunityBio, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue up 121% to $183M over 12 months, but shares fell 30% in one month.

  • BadFree cash flow was negative $297M over the last 12 months
  • BadShort interest is 12% of shares, taking 10.8 days to cover

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
691
Website
immunitybio.com
Listed
Nasdaq, US
Last results
9 Nov 2026
Next results
expected around 14 Jan 2027 (an estimate: a year ago it reported on 15 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $48.8M, net loss $184.6M.
Quarter to 31 Mar 2022: revenue $14K, net income -$102.8MQuarter to 31 Mar 2022: revenue $14K, net income -$102.8MQuarter to 30 Jun 2022: revenue $35K, net income -$94.6MQuarter to 30 Jun 2022: revenue $35K, net income -$94.6MQuarter to 30 Sep 2022: revenue $118K, net income -$110.9MQuarter to 30 Sep 2022: revenue $118K, net income -$110.9MQuarter to 31 Mar 2023: revenue $360K, net income -$116.3MQuarter to 31 Mar 2023: revenue $360K, net income -$116.3MQuarter to 30 Jun 2023: revenue $41K, net income -$137.9MQuarter to 30 Jun 2023: revenue $41K, net income -$137.9MQuarter to 30 Sep 2023: revenue $82K, net income -$95.6MQuarter to 30 Sep 2023: revenue $82K, net income -$95.6MQuarter to 31 Dec 2023: revenue $139K, net income -$233.4MQuarter to 31 Dec 2023: revenue $139K, net income -$233.4MQuarter to 31 Mar 2024: revenue $40K, net income -$134.1MQuarter to 31 Mar 2024: revenue $40K, net income -$134.1MQuarter to 30 Jun 2024: revenue $1.0M, net income -$134.6MQuarter to 30 Jun 2024: revenue $1.0M, net income -$134.6MQuarter to 30 Sep 2024: revenue $6.1M, net income -$85.7MQuarter to 30 Sep 2024: revenue $6.1M, net income -$85.7MQuarter to 31 Dec 2024: revenue –, net income -$59.2MQuarter to 31 Mar 2025: revenue $16.5M, net income -$129.6MQuarter to 31 Mar 2025: revenue $16.5M, net income -$129.6MQuarter to 30 Jun 2025: revenue $26.4M, net income -$92.6MQuarter to 30 Jun 2025: revenue $26.4M, net income -$92.6MQuarter to 30 Sep 2025: revenue $32.1M, net income -$67.3MQuarter to 30 Sep 2025: revenue $32.1M, net income -$67.3MQuarter to 31 Dec 2025: revenue $38.3M, net income -$61.9MQuarter to 31 Dec 2025: revenue $38.3M, net income -$61.9MQuarter to 31 Mar 2026: revenue $44.2M, net income -$632.8MQuarter to 31 Mar 2026: revenue $44.2M, net income -$632.8MQuarter to 30 Jun 2026: revenue $51.2M, net income -$230.4MQuarter to 30 Jun 2026: revenue $51.2M, net income -$230.4MQuarter to 30 Sep 2026: revenue $48.8M, net income -$184.6MQuarter to 30 Sep 2026: revenue $48.8M, net income -$184.6M
31 Mar 2022RevenueNet incomeNet losstallest bar $632.8M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$48.8M-$184.6M
30 Jun 2026$51.2M-$230.4M
31 Mar 2026$44.2M-$632.8M
31 Dec 2025$38.3M-$61.9M
30 Sep 2025$32.1M-$67.3M
30 Jun 2025$26.4M-$92.6M
31 Mar 2025$16.5M-$129.6M
31 Dec 2024–-$59.2M
30 Sep 2024$6.1M-$85.7M
30 Jun 2024$1.0M-$134.6M
31 Mar 2024$40K-$134.1M
31 Dec 2023$139K-$233.4M
30 Sep 2023$82K-$95.6M
30 Jun 2023$41K-$137.9M
31 Mar 2023$360K-$116.3M
30 Sep 2022$118K-$110.9M
30 Jun 2022$35K-$94.6M
31 Mar 2022$14K-$102.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $182.6M $82.6M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +121% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$1.1B -$348.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.08 -$0.41
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 98.8% 99.6% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -150% -316% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -608% -422% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$296.7M -$324.8M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $334.3M $257.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 35.1 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ImmunityBioIBRX (this company) $6.4Bloss35.1+121%-608%
Kodiak SciencesKOD $6.4Bloss–––
ImmunovantIMVT $6.6Bloss–––
Scholar RockSRRK $5.9Blossover 999––
Twist BioscienceTWST $7.0Bloss15.3+22%-28.3%
CG OncologyCGON $7.1Blossover 999+184%–

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$1.1M

bought $0, sold $1.1M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+1.3%

401 13F filers vs 396

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

19%

206.9M shares held by 13F filers (30 Sep 2026) of 1.1B outstanding (3 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

126.1M shares sold short (30 Oct 2026) of 1.1B outstanding (3 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.8

126.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+2.5%

122.9M shares sold short in the report before, 126.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

58%

58% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+52%

$48.8M vs $32.1M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$620K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

1

the 12 months before: 4

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

19

19 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

4.8×

19 articles in the last 7 days; its usual week has 4.

Price $6.02 on 20 Nov 2026, +198% over 12 months (12-month range $1.98 to $11.55)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $9.5M in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 7 published in the last 12 months, +17% on the 12 months before.
Revenue per quarter. Revenue $48.8M in the latest quarter, +52% on a year earlier.
Capital spending per quarter. Capital spending $2.9M in the latest quarter, +295% on a year earlier.
Institutional holders (13F filers). 401 13F filers reported holding it in the latest 13F quarter, +62% on a year earlier.
Lobbying spend. Lobbying spend: $620K published in the last 12 months (none in the 12 months before).
Workers in WARN layoff notices. Workers in WARN layoff notices: 1 published in the last 12 months, -75% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Jul 2026Lobbying filinglobbying engagement terminated (CONTINENTAL STRATEGY, LLC)
26 Jun 2026Lobbying filingnew lobbying registration (DRAKE VENTURES, LLC)
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 128 vs usual 36 (2026-03-31); 3.0x the same period a year earlier
12 May 2026Sharp changeShort interest spike: short interest spike, 138.1M vs usual 79.1M (2026-04-30); 2.0x the same period a year earlier
28 Apr 2026Sharp changeShort interest spike: short interest spike, 140.3M vs usual 77.0M (2026-04-15); 2.1x the same period a year earlier
14 Apr 2026Sharp changeShort interest spike: short interest spike, 135.5M vs usual 77.0M (2026-03-31); 2.1x the same period a year earlier
31 Mar 2026Sharp changeShort interest spike: short interest spike, 134.2M vs usual 76.1M (2026-03-13); 2.3x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 132.4M vs usual 75.2M (2026-02-27); 2.2x the same period a year earlier
3 Mar 2026Sharp changeShort interest spike: short interest spike, 134.7M vs usual 74.5M (2026-02-13); 2.4x the same period a year earlier
26 Feb 2026Sharp changeQuarterly revenue change: quarterly revenue change, 38.3M vs usual 6.8M (2025-12-31); 5.1x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 135.2M vs usual 73.7M (2026-01-30); 2.4x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 127.0M vs usual 73.6M (2026-01-15); 2.3x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 120.6M vs usual 73.0M (2025-12-31); 2.4x the same period a year earlier
30 Dec 2025Sharp changeShort interest spike: short interest spike, 109.0M vs usual 72.5M (2025-12-15); 2.5x the same period a year earlier
15 Dec 20258-K and other filingsDirector or officer change
15 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Dec 2025WARN layoff noticeImmunityBio, Inc., 1 workers, Woburn, MA, MA
9 Dec 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 1)
6 Nov 2025Sharp changeQuarterly revenue change: quarterly revenue change, 32.1M vs usual 3.6M (2025-09-30); 5.3x the same period a year earlier
22 Oct 2025Lobbying filingnew lobbying registration (CONTINENTAL STRATEGY, LLC)
7 Aug 2025Sharp changeQuarterly revenue change: quarterly revenue change, 26.4M vs usual 593K (2025-06-30); 25.2x the same period a year earlier
1 Jul 2025Sharp changeShort interest spike: short interest spike, 72.4M vs usual 52.7M (2025-06-13); 1.4x the same period a year earlier
20 Jun 20258-K and other filingsDirector or officer change
20 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Jun 2025Sharp changeShort interest spike: short interest spike, 72.1M vs usual 52.7M (2025-05-30); 1.3x the same period a year earlier
12 Jun 2025WARN layoff noticeImmunityBio. Inc., 3 workers, Woburn, MA
12 Jun 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 3)
3 Jun 2025Sharp changeShort interest spike: short interest spike, 73.7M vs usual 52.7M (2025-05-15); 1.4x the same period a year earlier
13 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 16.5M vs usual 128K (2025-03-31); 412.9x the same period a year earlier
19 Mar 20258-K and other filingsChanged its auditor
13 Feb 20258-K and other filingsDirector or officer change
7 Feb 20258-K and other filingsDirector or officer change
7 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Jan 2025WARN layoff noticeImmunity Bio. Inc., 1 workers, Burlington, MA
30 Jan 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 1)
27 Sep 2024WARN layoff noticeImmunityBio, Inc., 1 workers, Woburn, MA
27 Sep 2024Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 1)
5 Mar 2024Sharp changeShort interest spike: short interest spike, 47.1M vs usual 26.7M (2024-02-15); 2.0x the same period a year earlier
24 Feb 20248-K and other filingsDirector or officer change
24 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Jan 2024Sharp changeShort interest spike: short interest spike, 40.5M vs usual 25.2M (2023-12-29); 1.8x the same period a year earlier
2 Jan 2024Sharp changeShort interest spike: short interest spike, 37.8M vs usual 24.5M (2023-12-15); 1.6x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 36.1M vs usual 24.1M (2023-11-30); 1.5x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 35.7M vs usual 24.1M (2023-11-15); 1.5x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 41.9M vs usual 24.0M (2023-10-31); 1.8x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 41.6M vs usual 23.9M (2023-10-13); 1.8x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 39.5M vs usual 23.9M (2023-09-29); 1.6x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 36.4M vs usual 23.8M (2023-09-15); 1.7x the same period a year earlier
22 Sep 20238-K and other filingsPrivate placement of securities (Form D)
19 Aug 2023WARN layoff noticeImmunityBio, Inc., 2 workers, MA, MA
19 Aug 2023Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 2)
6 Jun 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 289K)
8 Oct 2022Lobbying filinglobbying engagement terminated (THE PETRIZZO GROUP, INC.)
22 Jul 20228-K and other filingsPrivate placement of securities (Form D)
19 Jul 2022Sharp changeShort interest spike: short interest spike, 18.5M vs usual 10.1M (2022-06-30); 2.0x the same period a year earlier
28 Jun 2022Sharp changeShort interest spike: short interest spike, 19.3M vs usual 9.7M (2022-06-15); 2.3x the same period a year earlier
14 Jun 2022Sharp changeShort interest spike: short interest spike, 18.5M vs usual 9.6M (2022-05-31); 2.3x the same period a year earlier
31 May 2022Sharp changeShort interest spike: short interest spike, 17.0M vs usual 9.5M (2022-05-13); 2.1x the same period a year earlier
17 May 2022Sharp changeShort interest spike: short interest spike, 17.2M vs usual 9.5M (2022-04-29); 2.5x the same period a year earlier
17 May 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 27.3M vs usual 546K (2022-03-31); 3.9x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 16.5M vs usual 9.4M (2022-04-14); 2.3x the same period a year earlier
12 Apr 2022Sharp changeShort interest spike: short interest spike, 15.9M vs usual 9.3M (2022-03-31); 2.3x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 16.7M vs usual 9.2M (2022-03-15); 3.7x the same period a year earlier
25 Mar 20228-K and other filingsDirector or officer change
25 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Feb 20228-K and other filingsCompleted an acquisition or asset sale
Insider net buying (open market)
Month from 1 Jun 2023: $289K published
Month from 1 Jan 2026: -$1.5M published
Month from 1 Feb 2026: -$2.9M published
Month from 1 Jun 2026: -$362K published
Month from 1 Jul 2026: -$3.6M published
Month from 1 Oct 2026: -$1.1M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Jul 2022: 6 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 3 published
Quarter from 1 Oct 2023: 2 published
Quarter from 1 Jan 2024: 2 published
Quarter from 1 Jul 2024: 2 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Jul 2025: 2 published
Quarter from 1 Oct 2025: 3 published
Quarter from 1 Jan 2026: 2 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 3 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Mar 2022: $14K, -90% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $35K, -90% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $118K, +79% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Mar 2023: $360K, +2471% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $41K, +17% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $82K, -31% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $139K; public on 20 Mar 2024
Quarter ended 31 Mar 2024: $40K, -89% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $1.0M, +2454% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $6.1M, +7346% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Mar 2025: $16.5M, +41192% on a year earlier; public on 13 May 2025
Quarter ended 30 Jun 2025: $26.4M, +2424% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $32.1M, +425% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $38.3M; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $44.2M, +168% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $51.2M, +94% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $48.8M, +52% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $27.3M, +286% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $15.9M; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $15.9M; public on 10 Nov 2022
Quarter ended 31 Mar 2023: $8.4M, -69% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $8.5M, -47% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $5.7M, -64% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $8.0M; public on 20 Mar 2024
Quarter ended 31 Mar 2024: $1.3M, -85% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $724K, -92% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $2.8M, -51% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $2.1M, -73% on a year earlier; public on 4 Mar 2025
Quarter ended 31 Mar 2025: $1.1M, -11% on a year earlier; public on 13 May 2025
Quarter ended 30 Jun 2025: $1.1M, +49% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $741K, -73% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $903K, -57% on a year earlier; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $1.8M, +58% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $3.5M, +225% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $2.9M, +295% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 130; public on 14 Feb 2022
31 Mar 2022 report: 143; public on 16 May 2022
30 Jun 2022 report: 127; public on 15 Aug 2022
30 Sep 2022 report: 117; public on 14 Nov 2022
31 Dec 2022 report: 126; public on 14 Feb 2023
31 Mar 2023 report: 139; public on 15 May 2023
30 Jun 2023 report: 104; public on 14 Aug 2023
30 Sep 2023 report: 124; public on 14 Nov 2023
31 Dec 2023 report: 137; public on 14 Feb 2024
31 Mar 2024 report: 156; public on 15 May 2024
30 Jun 2024 report: 180; public on 14 Aug 2024
30 Sep 2024 report: 173; public on 14 Nov 2024
31 Dec 2024 report: 194; public on 14 Feb 2025
31 Mar 2025 report: 204; public on 15 May 2025
30 Jun 2025 report: 227; public on 14 Aug 2025
30 Sep 2025 report: 248; public on 14 Nov 2025
31 Dec 2025 report: 258; public on 17 Feb 2026
31 Mar 2026 report: 374; public on 15 May 2026
30 Jun 2026 report: 396; public on 14 Aug 2026
30 Sep 2026 report: 401; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $60K published
Quarter from 1 Apr 2022: $60K published
Quarter from 1 Jul 2022: $45K published
Quarter from 1 Oct 2022: $45K published
Quarter from 1 Jan 2026: $60K published
Quarter from 1 Apr 2026: $60K published
Quarter from 1 Jul 2026: $200K published
Quarter from 1 Oct 2026: $300K published
Workers in WARN layoff notices
Month from 1 Aug 2023: 2 published
Month from 1 Sep 2024: 1 published
Month from 1 Jan 2025: 1 published
Month from 1 Jun 2025: 3 published
Month from 1 Dec 2025: 1 published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $300K (30 Sep 2026), 5.0× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $9.5M in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 7 published in the last 12 months, +17% on the 12 months before.
  • Revenue per quarter: Revenue $48.8M in the latest quarter, +52% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 62 insider trades

Last 90 days: 2 sales, $1.1M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
6 Oct 2026Barry J. SimonDirectorSellplanned in advance (10b5-1)25,000$10.75$269KForm 4
6 Oct 2026Cheryl CohenDirectorSellplanned in advance (10b5-1); after exercising options81,056$10.50$851KForm 4
6 Jul 2026Cheryl CohenDirectorSellplanned in advance (10b5-1); after exercising options131,210$9.50$1.2MForm 4
6 Jul 2026Christobel SeleckyDirectorSellplanned in advance (10b5-1); after exercising options159,478$9.02$1.4MForm 4
1 Jul 2026Christobel SeleckyDirectorSellplanned in advance (10b5-1); after exercising options96,722$9.01$871KForm 4
26 Jun 2026Barry J. SimonDirectorSellplanned in advance (10b5-1)25,000$7.88$197KForm 4
5 Jun 2026Barry J. SimonDirectorSellplanned in advance (10b5-1)23,033$7.18$165KForm 4
26 Feb 2026Barry J. SimonDirectorSellplanned in advance (10b5-1)75,000$12.01$901KForm 4

401 institutions reported shares at the end of Q3 2026, 19% of the shares outstanding; 48 opened a position, 46 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.36.1M3.40%$341.0M+2.0M+6.0%
State Street Corp21.1M1.98%$199.1M-303K-1.4%
Vanguard Portfolio Management LLC19.4M1.82%$183.0M+1.5M+8.5%
Vanguard Capital Management LLC18.8M1.77%$177.5M+3.1M+20%
D. E. Shaw & Co., Inc.10.7M1.01%$101.1M-839K-7.3%
Geode Capital Management, LLC10.6M1.00%$100.1M+759K+7.7%
Two Sigma Investments, LP5.8M0.55%$55.0M-5.3M-47%
Charles Schwab Investment Management Inc4.9M0.46%$46.6M+2.0M+71%
Goldman Sachs Group Inc4.1M0.39%$39.0M+896K+28%
Millennium Management LLC3.8M0.36%$36.0M-1.8M-32%

Company events

All 51 company events

In 12 months: 4 major agreements, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
18 May 2026Signed a major agreement8-K
31 Mar 2026Signed a major agreementSame filing: took on new debt8-K
26 Jan 2026Signed a major agreement8-K
23 Dec 2025Signed a major agreement8-K
15 Dec 2025Director or officer change8-K
25 Jul 2025Signed a major agreement8-K
20 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
8 Apr 2025Signed a major agreement8-K

Reported lobbying spend: $300K in Q3 2026, $200K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Jun 2026EndedContinental Strategy, LLCfor Immunitybio, Inc.Not statedFiling
24 Apr 2026NewDrake Ventures, LLCfor Immunity Bio, IncAnti-cancer TreatmentsHealth issuesFiling
1 Oct 2025NewContinental Strategy, LLCfor Immunitybio, Inc.Opportunities, funding, and support for medical research, development, and manufacturing of certain cancer treatments.MED, Health issuesFiling
30 Sep 2022EndedThe Petrizzo Group, Inc.for Immunitybio, Inc.Federal support for next generation COVID-19 vaccine technology research, development and manufacturing, approval and distribution.; Federal support for next generation COVID-19 vaccine technology research, development and manufacturing approval and distribution.MED, Health issuesFiling
15 Oct 2021NewThe Petrizzo Group, Inc.for Immunitybio, Inc.New Technologies for Accessible, Durable, and Broadly Protective 2nd Generation Coronavirus VaccinesMED, Science/technology, Health issuesFiling

Layoff notices

All 5 layoff notices

1 notice in 12 months covering 1 workers. State WARN notices.

NoticeSiteWorkersJobs endSource
8 Dec 2025ImmunityBio, Inc.Woburn, MA, MA130 Jan 2026Notice
11 Jun 2025ImmunityBio. Inc.Woburn, MA329 Jul 2025Notice
29 Jan 2025Immunity Bio. Inc.Burlington, MA125 Mar 2025Notice
26 Sep 2024ImmunityBio, Inc.Woburn, MA125 Nov 2024Notice
18 Aug 2023ImmunityBio, Inc.MA, MA217 Oct 2023Notice

The 5 newest of 321 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

30 Dec 2025confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Layoff notices and Short interest and volume

ImmunityBio (IBRX): filed a WARN layoff notice covering 1 workers within 30 days (Woburn, MA, MA); it also had 135.2M shares sold short in the 30 Jan 2026 report, 2.4× the same report last year; it also reported revenue of $38.3M for the quarter ended 31 Dec 2025, 5.1× the same quarter last year; and it saw 128 13F filers open a new position in the quarter ended 31 Mar 2026, 3.0× the same quarter last year. Four unrelated kinds of activity within 161 days.

  • Layoff notices: WARN layoff notice, became public on 9 Dec 2025
  • Short interest and volume: Short interest spike, became public on 25 Dec 2025
  • Short interest and volume: Short interest spike, became public on 13 Jan 2026
  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
  • Financials: Quarterly revenue change, became public on 26 Feb 2026
  • Short interest and volume: Short interest spike, became public on 26 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Mar 2026
  • Short interest and volume: Short interest spike, became public on 25 Mar 2026
  • Short interest and volume: Short interest spike, became public on 11 Apr 2026
  • Short interest and volume: Short interest spike, became public on 25 Apr 2026
  • Short interest and volume: Short interest spike, became public on 12 May 2026
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2026
2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M
The 30 Jan 2026 report against the 24 reports before it. this reportearliernormal: 73.7M
See the evidence (13 changes)

Layoff notices: WARN layoff notice became public on 9 Dec 2025

ImmunityBio filed a WARN layoff notice covering 1 workers within 30 days (Woburn, MA, MA).

Notices in the window
1
Workers named
1
Window
9 Nov 2025 to 9 Dec 2025

Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

Short interest and volume: Short interest spike became public on 25 Dec 2025

ImmunityBio had 109.0M shares sold short in the 15 Dec 2025 report, 2.5× the same report last year.

This period
109.0M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
72.5M
Typical spread (median absolute deviation)
4.9M
How far from its usual level
+5.0
Same report last year
44.4M
History used
1,736 days
2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M
the 15 Dec 2025 report24 earlier reportsnormal: 72.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Jan 2026

ImmunityBio had 120.6M shares sold short in the 31 Dec 2025 report, 2.4× the same report last year.

This period
120.6M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
73.0M
Typical spread (median absolute deviation)
5.0M
How far from its usual level
+6.4
Same report last year
50.0M
History used
1,752 days
2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M
the 31 Dec 2025 report24 earlier reportsnormal: 73.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Jan 2026

ImmunityBio had 127.0M shares sold short in the 15 Jan 2026 report, 2.3× the same report last year.

This period
127.0M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
73.6M
Typical spread (median absolute deviation)
5.6M
How far from its usual level
+6.4
Same report last year
54.5M
History used
1,767 days
2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M
the 15 Jan 2026 report24 earlier reportsnormal: 73.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Feb 2026

ImmunityBio had 135.2M shares sold short in the 30 Jan 2026 report, 2.4× the same report last year.

This period
135.2M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
73.7M
Typical spread (median absolute deviation)
5.8M
How far from its usual level
+7.2
Same report last year
55.9M
History used
1,782 days
2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M
the 30 Jan 2026 report24 earlier reportsnormal: 73.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 26 Feb 2026

ImmunityBio reported revenue of $38.3M for the quarter ended 31 Dec 2025, 5.1× the same quarter last year.

This period
$38.3M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$6.8M
Typical spread (median absolute deviation)
$6.7M
How far from its usual level
+3.1
Same quarter last year
$7.6M
History used
3,562 days
2023-12-31: $139K2024-03-31: $40K2024-06-30: $1.0M2024-09-30: $6.1M2024-12-31: $7.6M2025-03-31: $16.5M2025-06-30: $26.4M2025-09-30: $32.1M2025-12-31: $38.3M
the quarter ended 31 Dec 20258 earlier quartersnormal: $6.8M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 26 Feb 2026

ImmunityBio had 134.7M shares sold short in the 13 Feb 2026 report, 2.4× the same report last year.

This period
134.7M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
74.5M
Typical spread (median absolute deviation)
6.2M
How far from its usual level
+6.6
Same report last year
57.0M
History used
1,796 days
2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M
the 13 Feb 2026 report24 earlier reportsnormal: 74.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Mar 2026

ImmunityBio had 132.4M shares sold short in the 27 Feb 2026 report, 2.2× the same report last year.

This period
132.4M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
75.2M
Typical spread (median absolute deviation)
6.2M
How far from its usual level
+6.3
Same report last year
60.9M
History used
1,810 days
2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M
the 27 Feb 2026 report24 earlier reportsnormal: 75.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Mar 2026

ImmunityBio had 134.2M shares sold short in the 13 Mar 2026 report, 2.3× the same report last year.

This period
134.2M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
76.1M
Typical spread (median absolute deviation)
6.2M
How far from its usual level
+6.4
Same report last year
59.5M
History used
1,824 days
2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M
the 13 Mar 2026 report24 earlier reportsnormal: 76.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Apr 2026

ImmunityBio had 135.5M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.

This period
135.5M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
77.0M
Typical spread (median absolute deviation)
6.2M
How far from its usual level
+6.4
Same report last year
63.2M
History used
1,842 days
2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M2026-03-31: 135.5M
the 31 Mar 2026 report24 earlier reportsnormal: 77.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Apr 2026

ImmunityBio had 140.3M shares sold short in the 15 Apr 2026 report, 2.1× the same report last year.

This period
140.3M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
77.0M
Typical spread (median absolute deviation)
6.2M
How far from its usual level
+6.9
Same report last year
67.2M
History used
1,857 days
2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M2026-03-31: 135.5M2026-04-15: 140.3M
the 15 Apr 2026 report24 earlier reportsnormal: 77.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 May 2026

ImmunityBio had 138.1M shares sold short in the 30 Apr 2026 report, 2.0× the same report last year.

This period
138.1M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
79.1M
Typical spread (median absolute deviation)
6.8M
How far from its usual level
+5.8
Same report last year
68.8M
History used
1,872 days
2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M2026-03-31: 135.5M2026-04-15: 140.3M2026-04-30: 138.1M
the 30 Apr 2026 report24 earlier reportsnormal: 79.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2026

ImmunityBio saw 128 13F filers open a new position in the quarter ended 31 Mar 2026, 3.0× the same quarter last year.

This period
128 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
36
Typical spread (median absolute deviation)
6
How far from its usual level
+10.3
Same quarter last year
43
History used
1,826 days
2024-03-31: 312024-06-30: 392024-09-30: 182024-12-31: 332025-03-31: 432025-06-30: 552025-09-30: 442025-12-31: 332026-03-31: 128
the quarter ended 31 Mar 20268 earlier quartersnormal: 36

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

3 Jun 2025confirmed

Confirmed across sources Filings + Financials and Layoff notices and Short interest and volume

ImmunityBio (IBRX): reported revenue of $16.5M for the quarter ended 31 Mar 2025, 413× the same quarter last year; it also had 73.7M shares sold short in the 15 May 2025 report, 1.4× the same report last year; and it filed a WARN layoff notice covering 3 workers within 30 days (Woburn, MA). Three unrelated kinds of activity within 49 days.

  • Financials: Quarterly revenue change, became public on 13 May 2025
  • Short interest and volume: Short interest spike, became public on 28 May 2025
  • Layoff notices: WARN layoff notice, became public on 12 Jun 2025
  • Short interest and volume: Short interest spike, became public on 11 Jun 2025
  • Short interest and volume: Short interest spike, became public on 26 Jun 2025
2022-09-30: $118K2023-03-31: $360K2023-06-30: $41K2023-09-30: $82K2023-12-31: $139K2024-03-31: $40K2024-06-30: $1.0M2024-09-30: $6.1M2025-03-31: $16.5M
The quarter ended 31 Mar 2025 against the 8 quarters before it. this quarterearliernormal: $128K
See the evidence (5 changes)

Financials: Quarterly revenue change became public on 13 May 2025

ImmunityBio reported revenue of $16.5M for the quarter ended 31 Mar 2025, 413× the same quarter last year.

This period
$16.5M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$128K
Typical spread (median absolute deviation)
$88K
How far from its usual level
+16.4
Same quarter last year
$40K
History used
4,018 days
2022-09-30: $118K2023-03-31: $360K2023-06-30: $41K2023-09-30: $82K2023-12-31: $139K2024-03-31: $40K2024-06-30: $1.0M2024-09-30: $6.1M2025-03-31: $16.5M
the quarter ended 31 Mar 20258 earlier quartersnormal: $128K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 28 May 2025

ImmunityBio had 73.7M shares sold short in the 15 May 2025 report, 1.4× the same report last year.

This period
73.7M (the 15 May 2025 report)
Normal report (median of 24 earlier)
52.7M
Typical spread (median absolute deviation)
3.1M
How far from its usual level
+4.0
Same report last year
53.4M
History used
1,522 days
2024-05-15: 53.4M2024-05-31: 53.5M2024-06-14: 53.4M2024-06-28: 49.1M2024-07-15: 48.5M2024-07-31: 46.8M2024-08-15: 49.2M2024-08-30: 51.3M2024-09-13: 50.7M2024-09-30: 52.7M2024-10-15: 51.6M2024-10-31: 52.7M2024-11-15: 52.1M2024-11-29: 49.8M2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M
the 15 May 2025 report24 earlier reportsnormal: 52.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Layoff notices: WARN layoff notice became public on 12 Jun 2025

ImmunityBio filed a WARN layoff notice covering 3 workers within 30 days (Woburn, MA).

Notices in the window
1
Workers named
3
Window
13 May 2025 to 12 Jun 2025

Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

Short interest and volume: Short interest spike became public on 11 Jun 2025

ImmunityBio had 72.1M shares sold short in the 30 May 2025 report, 1.3× the same report last year.

This period
72.1M (the 30 May 2025 report)
Normal report (median of 24 earlier)
52.7M
Typical spread (median absolute deviation)
3.4M
How far from its usual level
+3.7
Same report last year
53.5M
History used
1,537 days
2024-05-31: 53.5M2024-06-14: 53.4M2024-06-28: 49.1M2024-07-15: 48.5M2024-07-31: 46.8M2024-08-15: 49.2M2024-08-30: 51.3M2024-09-13: 50.7M2024-09-30: 52.7M2024-10-15: 51.6M2024-10-31: 52.7M2024-11-15: 52.1M2024-11-29: 49.8M2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M
the 30 May 2025 report24 earlier reportsnormal: 52.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jun 2025

ImmunityBio had 72.4M shares sold short in the 13 Jun 2025 report, 1.4× the same report last year.

This period
72.4M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
52.7M
Typical spread (median absolute deviation)
3.6M
How far from its usual level
+3.7
Same report last year
53.4M
History used
1,551 days
2024-06-14: 53.4M2024-06-28: 49.1M2024-07-15: 48.5M2024-07-31: 46.8M2024-08-15: 49.2M2024-08-30: 51.3M2024-09-13: 50.7M2024-09-30: 52.7M2024-10-15: 51.6M2024-10-31: 52.7M2024-11-15: 52.1M2024-11-29: 49.8M2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M
the 13 Jun 2025 report24 earlier reportsnormal: 52.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

17 May 2022confirmed

Confirmed across sources Filings + Financials and Short interest and volume

ImmunityBio (IBRX): spent $27.3M on capital projects in the quarter ended 31 Mar 2022, 3.9× the same quarter last year, while it had 19.3M shares sold short in the 15 Jun 2022 report, 2.3× the same report last year. Two unrelated kinds of activity within 77 days.

  • Short interest and volume: Short interest spike, became public on 27 Apr 2022
  • Financials: Quarterly capital spending jump, became public on 17 May 2022
  • Short interest and volume: Short interest spike, became public on 11 May 2022
  • Short interest and volume: Short interest spike, became public on 25 May 2022
  • Short interest and volume: Short interest spike, became public on 10 Jun 2022
  • Short interest and volume: Short interest spike, became public on 28 Jun 2022
  • Short interest and volume: Short interest spike, became public on 13 Jul 2022
2019-06-30: $985K2019-09-30: $413K2019-12-31: $680K2020-03-31: $146K2020-06-30: $394K2020-09-30: $1.7M2020-12-31: $401K2021-03-31: $7.1M2022-03-31: $27.3M
The quarter ended 31 Mar 2022 against the 8 quarters before it. this quarterearliernormal: $546K
See the evidence (7 changes)

Short interest and volume: Short interest spike became public on 27 Apr 2022

ImmunityBio had 16.5M shares sold short in the 14 Apr 2022 report, 2.3× the same report last year.

This period
16.5M (the 14 Apr 2022 report)
Normal report (median of 24 earlier)
9.4M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+4.5
Same report last year
7.2M
History used
395 days
2021-03-31: 6.8M2021-04-15: 7.2M2021-04-30: 6.9M2021-05-14: 8.0M2021-05-28: 8.0M2021-06-15: 8.3M2021-06-30: 9.4M2021-07-15: 8.9M2021-07-30: 9.5M2021-08-13: 9.6M2021-08-31: 9.2M2021-09-15: 9.4M2021-09-30: 9.7M2021-10-15: 9.2M2021-10-29: 8.9M2021-11-15: 9.1M2021-11-30: 9.5M2021-12-15: 10.4M2022-01-14: 12.4M2022-01-31: 13.0M2022-02-15: 14.6M2022-02-28: 16.3M2022-03-15: 16.7M2022-03-31: 15.9M2022-04-14: 16.5M
the 14 Apr 2022 report24 earlier reportsnormal: 9.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly capital spending jump became public on 17 May 2022

ImmunityBio spent $27.3M on capital projects in the quarter ended 31 Mar 2022, 3.9× the same quarter last year.

This period
$27.3M (the quarter ended 31 Mar 2022)
Normal quarter (median of 8 earlier)
$546K
Typical spread (median absolute deviation)
$276K
How far from its usual level
+26.8
Same quarter last year
$7.1M
History used
2,739 days
2019-06-30: $985K2019-09-30: $413K2019-12-31: $680K2020-03-31: $146K2020-06-30: $394K2020-09-30: $1.7M2020-12-31: $401K2021-03-31: $7.1M2022-03-31: $27.3M
the quarter ended 31 Mar 20228 earlier quartersnormal: $546K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 11 May 2022

ImmunityBio had 17.2M shares sold short in the 29 Apr 2022 report, 2.5× the same report last year.

This period
17.2M (the 29 Apr 2022 report)
Normal report (median of 24 earlier)
9.5M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+4.9
Same report last year
6.9M
History used
410 days
2021-04-15: 7.2M2021-04-30: 6.9M2021-05-14: 8.0M2021-05-28: 8.0M2021-06-15: 8.3M2021-06-30: 9.4M2021-07-15: 8.9M2021-07-30: 9.5M2021-08-13: 9.6M2021-08-31: 9.2M2021-09-15: 9.4M2021-09-30: 9.7M2021-10-15: 9.2M2021-10-29: 8.9M2021-11-15: 9.1M2021-11-30: 9.5M2021-12-15: 10.4M2022-01-14: 12.4M2022-01-31: 13.0M2022-02-15: 14.6M2022-02-28: 16.3M2022-03-15: 16.7M2022-03-31: 15.9M2022-04-14: 16.5M2022-04-29: 17.2M
the 29 Apr 2022 report24 earlier reportsnormal: 9.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 May 2022

ImmunityBio had 17.0M shares sold short in the 13 May 2022 report, 2.1× the same report last year.

This period
17.0M (the 13 May 2022 report)
Normal report (median of 24 earlier)
9.5M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+4.7
Same report last year
8.0M
History used
424 days
2021-04-30: 6.9M2021-05-14: 8.0M2021-05-28: 8.0M2021-06-15: 8.3M2021-06-30: 9.4M2021-07-15: 8.9M2021-07-30: 9.5M2021-08-13: 9.6M2021-08-31: 9.2M2021-09-15: 9.4M2021-09-30: 9.7M2021-10-15: 9.2M2021-10-29: 8.9M2021-11-15: 9.1M2021-11-30: 9.5M2021-12-15: 10.4M2022-01-14: 12.4M2022-01-31: 13.0M2022-02-15: 14.6M2022-02-28: 16.3M2022-03-15: 16.7M2022-03-31: 15.9M2022-04-14: 16.5M2022-04-29: 17.2M2022-05-13: 17.0M
the 13 May 2022 report24 earlier reportsnormal: 9.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Jun 2022

ImmunityBio had 18.5M shares sold short in the 31 May 2022 report, 2.3× the same report last year.

This period
18.5M (the 31 May 2022 report)
Normal report (median of 24 earlier)
9.6M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+5.6
Same report last year
8.0M
History used
442 days
2021-05-14: 8.0M2021-05-28: 8.0M2021-06-15: 8.3M2021-06-30: 9.4M2021-07-15: 8.9M2021-07-30: 9.5M2021-08-13: 9.6M2021-08-31: 9.2M2021-09-15: 9.4M2021-09-30: 9.7M2021-10-15: 9.2M2021-10-29: 8.9M2021-11-15: 9.1M2021-11-30: 9.5M2021-12-15: 10.4M2022-01-14: 12.4M2022-01-31: 13.0M2022-02-15: 14.6M2022-02-28: 16.3M2022-03-15: 16.7M2022-03-31: 15.9M2022-04-14: 16.5M2022-04-29: 17.2M2022-05-13: 17.0M2022-05-31: 18.5M
the 31 May 2022 report24 earlier reportsnormal: 9.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Jun 2022

ImmunityBio had 19.3M shares sold short in the 15 Jun 2022 report, 2.3× the same report last year.

This period
19.3M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
9.7M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+5.9
Same report last year
8.3M
History used
457 days
2021-05-28: 8.0M2021-06-15: 8.3M2021-06-30: 9.4M2021-07-15: 8.9M2021-07-30: 9.5M2021-08-13: 9.6M2021-08-31: 9.2M2021-09-15: 9.4M2021-09-30: 9.7M2021-10-15: 9.2M2021-10-29: 8.9M2021-11-15: 9.1M2021-11-30: 9.5M2021-12-15: 10.4M2022-01-14: 12.4M2022-01-31: 13.0M2022-02-15: 14.6M2022-02-28: 16.3M2022-03-15: 16.7M2022-03-31: 15.9M2022-04-14: 16.5M2022-04-29: 17.2M2022-05-13: 17.0M2022-05-31: 18.5M2022-06-15: 19.3M
the 15 Jun 2022 report24 earlier reportsnormal: 9.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Jul 2022

ImmunityBio had 18.5M shares sold short in the 30 Jun 2022 report, 2.0× the same report last year.

This period
18.5M (the 30 Jun 2022 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
1.5M
How far from its usual level
+3.8
Same report last year
9.4M
History used
472 days
2021-06-15: 8.3M2021-06-30: 9.4M2021-07-15: 8.9M2021-07-30: 9.5M2021-08-13: 9.6M2021-08-31: 9.2M2021-09-15: 9.4M2021-09-30: 9.7M2021-10-15: 9.2M2021-10-29: 8.9M2021-11-15: 9.1M2021-11-30: 9.5M2021-12-15: 10.4M2022-01-14: 12.4M2022-01-31: 13.0M2022-02-15: 14.6M2022-02-28: 16.3M2022-03-15: 16.7M2022-03-31: 15.9M2022-04-14: 16.5M2022-04-29: 17.2M2022-05-13: 17.0M2022-05-31: 18.5M2022-06-15: 19.3M2022-06-30: 18.5M
the 30 Jun 2022 report24 earlier reportsnormal: 10.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 19 Jul 2026Lobbying record

    IMMUNITYBIO, INC.: lobbying engagement terminated (CONTINENTAL STRATEGY, LLC) (dated 30 Jun 2026)

  2. 26 Jun 2026Lobbying record

    IMMUNITY BIO, INC: new lobbying registration (DRAKE VENTURES, LLC) (dated 24 Apr 2026)

  3. 15 May 2026Institutional holdings change

    saw 128 13F filers open a new position in the quarter ended 31 Mar 2026, 3.0× the same quarter last year.

    Same quarter last year: 43; its normal quarter is 36.

    See the evidence
    This period
    128 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    36
    Typical spread (median absolute deviation)
    6
    How far from its usual level
    +10.3
    Same quarter last year
    43
    History used
    1,826 days
    2024-03-31: 312024-06-30: 392024-09-30: 182024-12-31: 332025-03-31: 432025-06-30: 552025-09-30: 442025-12-31: 332026-03-31: 128
    the quarter ended 31 Mar 20268 earlier quartersnormal: 36

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  4. 12 May 2026Short interest and volume change

    had 138.1M shares sold short in the 30 Apr 2026 report, 2.0× the same report last year.

    Same report last year: 68.8M; its normal report is 79.1M.

    See the evidence
    This period
    138.1M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    79.1M
    Typical spread (median absolute deviation)
    6.8M
    How far from its usual level
    +5.8
    Same report last year
    68.8M
    History used
    1,872 days
    2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M2026-03-31: 135.5M2026-04-15: 140.3M2026-04-30: 138.1M
    the 30 Apr 2026 report24 earlier reportsnormal: 79.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 25 Apr 2026Short interest and volume change

    had 140.3M shares sold short in the 15 Apr 2026 report, 2.1× the same report last year.

    Same report last year: 67.2M; its normal report is 77.0M.

    See the evidence
    This period
    140.3M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    77.0M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.9
    Same report last year
    67.2M
    History used
    1,857 days
    2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M2026-03-31: 135.5M2026-04-15: 140.3M
    the 15 Apr 2026 report24 earlier reportsnormal: 77.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 11 Apr 2026Short interest and volume change

    had 135.5M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.

    Same report last year: 63.2M; its normal report is 77.0M.

    See the evidence
    This period
    135.5M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    77.0M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.4
    Same report last year
    63.2M
    History used
    1,842 days
    2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M2026-03-31: 135.5M
    the 31 Mar 2026 report24 earlier reportsnormal: 77.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 25 Mar 2026Short interest and volume change

    had 134.2M shares sold short in the 13 Mar 2026 report, 2.3× the same report last year.

    Same report last year: 59.5M; its normal report is 76.1M.

    See the evidence
    This period
    134.2M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    76.1M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.4
    Same report last year
    59.5M
    History used
    1,824 days
    2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M
    the 13 Mar 2026 report24 earlier reportsnormal: 76.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 11 Mar 2026Short interest and volume change

    had 132.4M shares sold short in the 27 Feb 2026 report, 2.2× the same report last year.

    Same report last year: 60.9M; its normal report is 75.2M.

    See the evidence
    This period
    132.4M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    75.2M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.3
    Same report last year
    60.9M
    History used
    1,810 days
    2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M
    the 27 Feb 2026 report24 earlier reportsnormal: 75.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 26 Feb 2026Short interest and volume change

    had 134.7M shares sold short in the 13 Feb 2026 report, 2.4× the same report last year.

    Same report last year: 57.0M; its normal report is 74.5M.

    See the evidence
    This period
    134.7M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    74.5M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.6
    Same report last year
    57.0M
    History used
    1,796 days
    2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M
    the 13 Feb 2026 report24 earlier reportsnormal: 74.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 26 Feb 2026Financials change

    reported revenue of $38.3M for the quarter ended 31 Dec 2025, 5.1× the same quarter last year.

    Same quarter last year: $7.6M; its normal quarter is $6.8M.

    See the evidence
    This period
    $38.3M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $6.8M
    Typical spread (median absolute deviation)
    $6.7M
    How far from its usual level
    +3.1
    Same quarter last year
    $7.6M
    History used
    3,562 days
    2023-12-31: $139K2024-03-31: $40K2024-06-30: $1.0M2024-09-30: $6.1M2024-12-31: $7.6M2025-03-31: $16.5M2025-06-30: $26.4M2025-09-30: $32.1M2025-12-31: $38.3M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $6.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  11. 11 Feb 2026Short interest and volume change

    had 135.2M shares sold short in the 30 Jan 2026 report, 2.4× the same report last year.

    Same report last year: 55.9M; its normal report is 73.7M.

    See the evidence
    This period
    135.2M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    73.7M
    Typical spread (median absolute deviation)
    5.8M
    How far from its usual level
    +7.2
    Same report last year
    55.9M
    History used
    1,782 days
    2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M
    the 30 Jan 2026 report24 earlier reportsnormal: 73.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 28 Jan 2026Short interest and volume change

    had 127.0M shares sold short in the 15 Jan 2026 report, 2.3× the same report last year.

    Same report last year: 54.5M; its normal report is 73.6M.

    See the evidence
    This period
    127.0M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    73.6M
    Typical spread (median absolute deviation)
    5.6M
    How far from its usual level
    +6.4
    Same report last year
    54.5M
    History used
    1,767 days
    2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M
    the 15 Jan 2026 report24 earlier reportsnormal: 73.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 13 Jan 2026Short interest and volume change

    had 120.6M shares sold short in the 31 Dec 2025 report, 2.4× the same report last year.

    Same report last year: 50.0M; its normal report is 73.0M.

    See the evidence
    This period
    120.6M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    73.0M
    Typical spread (median absolute deviation)
    5.0M
    How far from its usual level
    +6.4
    Same report last year
    50.0M
    History used
    1,752 days
    2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M
    the 31 Dec 2025 report24 earlier reportsnormal: 73.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 30 Dec 2025several at once

    filed a WARN layoff notice covering 1 workers within 30 days (Woburn, MA, MA); it also had 135.2M shares sold short in the 30 Jan 2026 report, 2.4× the same report last year; it also reported revenue of $38.3M for the quarter ended 31 Dec 2025, 5.1× the same quarter last year; and it saw 128 13F filers open a new position in the quarter ended 31 Mar 2026, 3.0× the same quarter last year. Four unrelated kinds of activity within 161 days.

    See the evidence (13 changes)

    Layoff notices: WARN layoff notice became public on 9 Dec 2025

    ImmunityBio filed a WARN layoff notice covering 1 workers within 30 days (Woburn, MA, MA).

    Notices in the window
    1
    Workers named
    1
    Window
    9 Nov 2025 to 9 Dec 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

    Short interest and volume: Short interest spike became public on 25 Dec 2025

    ImmunityBio had 109.0M shares sold short in the 15 Dec 2025 report, 2.5× the same report last year.

    This period
    109.0M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    72.5M
    Typical spread (median absolute deviation)
    4.9M
    How far from its usual level
    +5.0
    Same report last year
    44.4M
    History used
    1,736 days
    2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M
    the 15 Dec 2025 report24 earlier reportsnormal: 72.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Jan 2026

    ImmunityBio had 120.6M shares sold short in the 31 Dec 2025 report, 2.4× the same report last year.

    This period
    120.6M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    73.0M
    Typical spread (median absolute deviation)
    5.0M
    How far from its usual level
    +6.4
    Same report last year
    50.0M
    History used
    1,752 days
    2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M
    the 31 Dec 2025 report24 earlier reportsnormal: 73.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    ImmunityBio had 127.0M shares sold short in the 15 Jan 2026 report, 2.3× the same report last year.

    This period
    127.0M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    73.6M
    Typical spread (median absolute deviation)
    5.6M
    How far from its usual level
    +6.4
    Same report last year
    54.5M
    History used
    1,767 days
    2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M
    the 15 Jan 2026 report24 earlier reportsnormal: 73.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    ImmunityBio had 135.2M shares sold short in the 30 Jan 2026 report, 2.4× the same report last year.

    This period
    135.2M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    73.7M
    Typical spread (median absolute deviation)
    5.8M
    How far from its usual level
    +7.2
    Same report last year
    55.9M
    History used
    1,782 days
    2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M
    the 30 Jan 2026 report24 earlier reportsnormal: 73.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 26 Feb 2026

    ImmunityBio reported revenue of $38.3M for the quarter ended 31 Dec 2025, 5.1× the same quarter last year.

    This period
    $38.3M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $6.8M
    Typical spread (median absolute deviation)
    $6.7M
    How far from its usual level
    +3.1
    Same quarter last year
    $7.6M
    History used
    3,562 days
    2023-12-31: $139K2024-03-31: $40K2024-06-30: $1.0M2024-09-30: $6.1M2024-12-31: $7.6M2025-03-31: $16.5M2025-06-30: $26.4M2025-09-30: $32.1M2025-12-31: $38.3M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $6.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 26 Feb 2026

    ImmunityBio had 134.7M shares sold short in the 13 Feb 2026 report, 2.4× the same report last year.

    This period
    134.7M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    74.5M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.6
    Same report last year
    57.0M
    History used
    1,796 days
    2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M
    the 13 Feb 2026 report24 earlier reportsnormal: 74.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Mar 2026

    ImmunityBio had 132.4M shares sold short in the 27 Feb 2026 report, 2.2× the same report last year.

    This period
    132.4M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    75.2M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.3
    Same report last year
    60.9M
    History used
    1,810 days
    2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M
    the 27 Feb 2026 report24 earlier reportsnormal: 75.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Mar 2026

    ImmunityBio had 134.2M shares sold short in the 13 Mar 2026 report, 2.3× the same report last year.

    This period
    134.2M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    76.1M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.4
    Same report last year
    59.5M
    History used
    1,824 days
    2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M
    the 13 Mar 2026 report24 earlier reportsnormal: 76.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Apr 2026

    ImmunityBio had 135.5M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.

    This period
    135.5M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    77.0M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.4
    Same report last year
    63.2M
    History used
    1,842 days
    2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M2026-03-31: 135.5M
    the 31 Mar 2026 report24 earlier reportsnormal: 77.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Apr 2026

    ImmunityBio had 140.3M shares sold short in the 15 Apr 2026 report, 2.1× the same report last year.

    This period
    140.3M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    77.0M
    Typical spread (median absolute deviation)
    6.2M
    How far from its usual level
    +6.9
    Same report last year
    67.2M
    History used
    1,857 days
    2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M2026-03-31: 135.5M2026-04-15: 140.3M
    the 15 Apr 2026 report24 earlier reportsnormal: 77.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 May 2026

    ImmunityBio had 138.1M shares sold short in the 30 Apr 2026 report, 2.0× the same report last year.

    This period
    138.1M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    79.1M
    Typical spread (median absolute deviation)
    6.8M
    How far from its usual level
    +5.8
    Same report last year
    68.8M
    History used
    1,872 days
    2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M2025-12-31: 120.6M2026-01-15: 127.0M2026-01-30: 135.2M2026-02-13: 134.7M2026-02-27: 132.4M2026-03-13: 134.2M2026-03-31: 135.5M2026-04-15: 140.3M2026-04-30: 138.1M
    the 30 Apr 2026 report24 earlier reportsnormal: 79.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 15 May 2026

    ImmunityBio saw 128 13F filers open a new position in the quarter ended 31 Mar 2026, 3.0× the same quarter last year.

    This period
    128 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    36
    Typical spread (median absolute deviation)
    6
    How far from its usual level
    +10.3
    Same quarter last year
    43
    History used
    1,826 days
    2024-03-31: 312024-06-30: 392024-09-30: 182024-12-31: 332025-03-31: 432025-06-30: 552025-09-30: 442025-12-31: 332026-03-31: 128
    the quarter ended 31 Mar 20268 earlier quartersnormal: 36

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  15. 25 Dec 2025Short interest and volume change

    had 109.0M shares sold short in the 15 Dec 2025 report, 2.5× the same report last year.

    Same report last year: 44.4M; its normal report is 72.5M.

    See the evidence
    This period
    109.0M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    72.5M
    Typical spread (median absolute deviation)
    4.9M
    How far from its usual level
    +5.0
    Same report last year
    44.4M
    History used
    1,736 days
    2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M2025-06-30: 77.0M2025-07-15: 77.0M2025-07-31: 77.1M2025-08-15: 75.2M2025-08-29: 75.3M2025-09-15: 84.6M2025-09-30: 73.4M2025-10-15: 72.6M2025-10-31: 73.8M2025-11-14: 81.1M2025-11-28: 88.6M2025-12-15: 109.0M
    the 15 Dec 2025 report24 earlier reportsnormal: 72.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 15 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 15 Dec 2025Filings record

    Director or officer change

  18. 9 Dec 2025Layoff notices change

    filed a WARN layoff notice covering 1 workers within 30 days (Woburn, MA, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    1
    Window
    9 Nov 2025 to 9 Dec 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  19. 9 Dec 2025Layoff notices record

    WARN notice: ImmunityBio, Inc., 1 workers, Woburn, MA, MA (dated 8 Dec 2025)

  20. 6 Nov 2025Financials change

    reported revenue of $32.1M for the quarter ended 30 Sep 2025, 5.3× the same quarter last year.

    Same quarter last year: $6.1M; its normal quarter is $3.6M.

    See the evidence
    This period
    $32.1M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $3.6M
    Typical spread (median absolute deviation)
    $3.5M
    How far from its usual level
    +5.5
    Same quarter last year
    $6.1M
    History used
    3,470 days
    2023-09-30: $82K2023-12-31: $139K2024-03-31: $40K2024-06-30: $1.0M2024-09-30: $6.1M2024-12-31: $7.6M2025-03-31: $16.5M2025-06-30: $26.4M2025-09-30: $32.1M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $3.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  21. 22 Oct 2025Lobbying record

    IMMUNITYBIO, INC.: new lobbying registration (CONTINENTAL STRATEGY, LLC) (dated 1 Oct 2025)

  22. 7 Aug 2025Financials change

    reported revenue of $26.4M for the quarter ended 30 Jun 2025, 25× the same quarter last year.

    Same quarter last year: $1.0M; its normal quarter is $593K.

    See the evidence
    This period
    $26.4M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $593K
    Typical spread (median absolute deviation)
    $552K
    How far from its usual level
    +25.8
    Same quarter last year
    $1.0M
    History used
    3,378 days
    2023-06-30: $41K2023-09-30: $82K2023-12-31: $139K2024-03-31: $40K2024-06-30: $1.0M2024-09-30: $6.1M2024-12-31: $7.6M2025-03-31: $16.5M2025-06-30: $26.4M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $593K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 26 Jun 2025Short interest and volume change

    had 72.4M shares sold short in the 13 Jun 2025 report, 1.4× the same report last year.

    Same report last year: 53.4M; its normal report is 52.7M.

    See the evidence
    This period
    72.4M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    52.7M
    Typical spread (median absolute deviation)
    3.6M
    How far from its usual level
    +3.7
    Same report last year
    53.4M
    History used
    1,551 days
    2024-06-14: 53.4M2024-06-28: 49.1M2024-07-15: 48.5M2024-07-31: 46.8M2024-08-15: 49.2M2024-08-30: 51.3M2024-09-13: 50.7M2024-09-30: 52.7M2024-10-15: 51.6M2024-10-31: 52.7M2024-11-15: 52.1M2024-11-29: 49.8M2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M
    the 13 Jun 2025 report24 earlier reportsnormal: 52.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 20 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  25. 20 Jun 2025Filings record

    Director or officer change

  26. 12 Jun 2025Layoff notices change

    filed a WARN layoff notice covering 3 workers within 30 days (Woburn, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    3
    Window
    13 May 2025 to 12 Jun 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  27. 12 Jun 2025Layoff notices record

    WARN notice: ImmunityBio. Inc., 3 workers, Woburn, MA (dated 11 Jun 2025)

  28. 11 Jun 2025Short interest and volume change

    had 72.1M shares sold short in the 30 May 2025 report, 1.3× the same report last year.

    Same report last year: 53.5M; its normal report is 52.7M.

    See the evidence
    This period
    72.1M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    52.7M
    Typical spread (median absolute deviation)
    3.4M
    How far from its usual level
    +3.7
    Same report last year
    53.5M
    History used
    1,537 days
    2024-05-31: 53.5M2024-06-14: 53.4M2024-06-28: 49.1M2024-07-15: 48.5M2024-07-31: 46.8M2024-08-15: 49.2M2024-08-30: 51.3M2024-09-13: 50.7M2024-09-30: 52.7M2024-10-15: 51.6M2024-10-31: 52.7M2024-11-15: 52.1M2024-11-29: 49.8M2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M
    the 30 May 2025 report24 earlier reportsnormal: 52.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 3 Jun 2025several at once

    reported revenue of $16.5M for the quarter ended 31 Mar 2025, 413× the same quarter last year; it also had 73.7M shares sold short in the 15 May 2025 report, 1.4× the same report last year; and it filed a WARN layoff notice covering 3 workers within 30 days (Woburn, MA). Three unrelated kinds of activity within 49 days.

    See the evidence (5 changes)

    Financials: Quarterly revenue change became public on 13 May 2025

    ImmunityBio reported revenue of $16.5M for the quarter ended 31 Mar 2025, 413× the same quarter last year.

    This period
    $16.5M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $128K
    Typical spread (median absolute deviation)
    $88K
    How far from its usual level
    +16.4
    Same quarter last year
    $40K
    History used
    4,018 days
    2022-09-30: $118K2023-03-31: $360K2023-06-30: $41K2023-09-30: $82K2023-12-31: $139K2024-03-31: $40K2024-06-30: $1.0M2024-09-30: $6.1M2025-03-31: $16.5M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $128K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 28 May 2025

    ImmunityBio had 73.7M shares sold short in the 15 May 2025 report, 1.4× the same report last year.

    This period
    73.7M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    52.7M
    Typical spread (median absolute deviation)
    3.1M
    How far from its usual level
    +4.0
    Same report last year
    53.4M
    History used
    1,522 days
    2024-05-15: 53.4M2024-05-31: 53.5M2024-06-14: 53.4M2024-06-28: 49.1M2024-07-15: 48.5M2024-07-31: 46.8M2024-08-15: 49.2M2024-08-30: 51.3M2024-09-13: 50.7M2024-09-30: 52.7M2024-10-15: 51.6M2024-10-31: 52.7M2024-11-15: 52.1M2024-11-29: 49.8M2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M
    the 15 May 2025 report24 earlier reportsnormal: 52.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Layoff notices: WARN layoff notice became public on 12 Jun 2025

    ImmunityBio filed a WARN layoff notice covering 3 workers within 30 days (Woburn, MA).

    Notices in the window
    1
    Workers named
    3
    Window
    13 May 2025 to 12 Jun 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

    Short interest and volume: Short interest spike became public on 11 Jun 2025

    ImmunityBio had 72.1M shares sold short in the 30 May 2025 report, 1.3× the same report last year.

    This period
    72.1M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    52.7M
    Typical spread (median absolute deviation)
    3.4M
    How far from its usual level
    +3.7
    Same report last year
    53.5M
    History used
    1,537 days
    2024-05-31: 53.5M2024-06-14: 53.4M2024-06-28: 49.1M2024-07-15: 48.5M2024-07-31: 46.8M2024-08-15: 49.2M2024-08-30: 51.3M2024-09-13: 50.7M2024-09-30: 52.7M2024-10-15: 51.6M2024-10-31: 52.7M2024-11-15: 52.1M2024-11-29: 49.8M2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M
    the 30 May 2025 report24 earlier reportsnormal: 52.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Jun 2025

    ImmunityBio had 72.4M shares sold short in the 13 Jun 2025 report, 1.4× the same report last year.

    This period
    72.4M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    52.7M
    Typical spread (median absolute deviation)
    3.6M
    How far from its usual level
    +3.7
    Same report last year
    53.4M
    History used
    1,551 days
    2024-06-14: 53.4M2024-06-28: 49.1M2024-07-15: 48.5M2024-07-31: 46.8M2024-08-15: 49.2M2024-08-30: 51.3M2024-09-13: 50.7M2024-09-30: 52.7M2024-10-15: 51.6M2024-10-31: 52.7M2024-11-15: 52.1M2024-11-29: 49.8M2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M2025-05-30: 72.1M2025-06-13: 72.4M
    the 13 Jun 2025 report24 earlier reportsnormal: 52.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  30. 28 May 2025Short interest and volume change

    had 73.7M shares sold short in the 15 May 2025 report, 1.4× the same report last year.

    Same report last year: 53.4M; its normal report is 52.7M.

    See the evidence
    This period
    73.7M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    52.7M
    Typical spread (median absolute deviation)
    3.1M
    How far from its usual level
    +4.0
    Same report last year
    53.4M
    History used
    1,522 days
    2024-05-15: 53.4M2024-05-31: 53.5M2024-06-14: 53.4M2024-06-28: 49.1M2024-07-15: 48.5M2024-07-31: 46.8M2024-08-15: 49.2M2024-08-30: 51.3M2024-09-13: 50.7M2024-09-30: 52.7M2024-10-15: 51.6M2024-10-31: 52.7M2024-11-15: 52.1M2024-11-29: 49.8M2024-12-13: 44.4M2024-12-31: 50.0M2025-01-15: 54.5M2025-01-31: 55.9M2025-02-14: 57.0M2025-02-28: 60.9M2025-03-14: 59.5M2025-03-31: 63.2M2025-04-15: 67.2M2025-04-30: 68.8M2025-05-15: 73.7M
    the 15 May 2025 report24 earlier reportsnormal: 52.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 13 May 2025Financials change

    reported revenue of $16.5M for the quarter ended 31 Mar 2025, 413× the same quarter last year.

    Same quarter last year: $40K; its normal quarter is $128K.

    See the evidence
    This period
    $16.5M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $128K
    Typical spread (median absolute deviation)
    $88K
    How far from its usual level
    +16.4
    Same quarter last year
    $40K
    History used
    4,018 days
    2022-09-30: $118K2023-03-31: $360K2023-06-30: $41K2023-09-30: $82K2023-12-31: $139K2024-03-31: $40K2024-06-30: $1.0M2024-09-30: $6.1M2025-03-31: $16.5M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $128K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  32. 19 Mar 2025Filings record

    Changed its auditor

  33. 13 Feb 2025Filings record

    Director or officer change (dated 12 Feb 2025)

  34. 7 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 7 Feb 2025Filings record

    Director or officer change

  36. 30 Jan 2025Layoff notices change

    filed a WARN layoff notice covering 1 workers within 30 days (Burlington, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    1
    Window
    31 Dec 2024 to 30 Jan 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  37. 30 Jan 2025Layoff notices record

    WARN notice: Immunity Bio. Inc., 1 workers, Burlington, MA (dated 29 Jan 2025)

  38. 27 Sep 2024Layoff notices change

    filed a WARN layoff notice covering 1 workers within 30 days (Woburn, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    1
    Window
    28 Aug 2024 to 27 Sep 2024

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  39. 27 Sep 2024Layoff notices record

    WARN notice: ImmunityBio, Inc., 1 workers, Woburn, MA (dated 26 Sep 2024)

  40. 28 Feb 2024Short interest and volume change

    had 47.1M shares sold short in the 15 Feb 2024 report, 2.0× the same report last year.

    Same report last year: 23.8M; its normal report is 26.7M.

    See the evidence
    This period
    47.1M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    26.7M
    Typical spread (median absolute deviation)
    3.9M
    How far from its usual level
    +3.5
    Same report last year
    23.8M
    History used
    1,067 days
    2023-02-15: 23.8M2023-02-28: 22.8M2023-03-15: 25.5M2023-03-31: 26.7M2023-04-14: 26.6M2023-04-28: 30.0M2023-05-15: 25.0M2023-05-31: 22.4M2023-06-15: 23.4M2023-06-30: 23.3M2023-07-14: 24.1M2023-07-31: 23.9M2023-08-15: 22.8M2023-08-31: 26.7M2023-09-15: 36.4M2023-09-29: 39.5M2023-10-13: 41.6M2023-10-31: 41.9M2023-11-15: 35.7M2023-11-30: 36.1M2023-12-15: 37.8M2023-12-29: 40.5M2024-01-12: 41.9M2024-01-31: 43.9M2024-02-15: 47.1M
    the 15 Feb 2024 report24 earlier reportsnormal: 26.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 99 entries; narrow the window or the kind of data to see older ones.

Not listed: 175 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001326110
Ticker
IBRX
Domain
immunitybio.com
Employer name
Immunity Bio. Inc., ImmunityBio, Inc. (2 unverified)
Hq location
CA|SAN DIEGO|92121 (1 unverified)
Lobbying client
immunity bio, immunitybio
Name
AccessBio LLC, Altor BioScience, LLC, Altor BioScience Manufacturing Company LLC, Conkwest, Inc. and 18 more
  • DOL H-1B labor condition applications and PERM certifications148 data points18 May 2020 to 14 Sep 2026
  • Federal lobbying disclosures (LDA)5 records, 24 data points15 Oct 2021 to 30 Sep 2026
  • SEC Form 13F institutional holdings207 data points31 Mar 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)145 records25 Jan 2016 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)737 data points31 Dec 2012 to 3 Nov 2026
  • SEC Form 4 insider transactions62 records, 204 data points11 Jul 2016 to 6 Oct 2026
  • FINRA short interest (twice monthly)405 data points15 Mar 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2868 data points10 Mar 2021 to 20 Nov 2026
  • WARN layoff notices (state labor agencies)5 records, 15 data points14 Aug 2023 to 8 Dec 2025